![Patrik Renblad](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrik Renblad
Direttore Finanziario/CFO presso CANTARGIA AB
Patrimonio netto: 25 102 $ in data 31/05/2024
Profilo
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A.
Mr. Renblad is a graduate of the University of Lund.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
CANTARGIA AB
0.03% | 31/12/2023 | 55 000 ( 0.03% ) | 25 102 $ | 31/05/2024 |
Posizioni attive di Patrik Renblad
Società | Posizione | Inizio |
---|---|---|
CANTARGIA AB | Direttore Finanziario/CFO | 15/06/2023 |
Precedenti posizioni note di Patrik Renblad
Società | Posizione | Fine |
---|---|---|
SYNACT PHARMA AB | Direttore Finanziario/CFO | 15/05/2023 |
LEO Pharma A/S
![]() LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Formazione di Patrik Renblad
University of Lund | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
SYNACT PHARMA AB | Health Technology |
CANTARGIA AB | Health Technology |
Aziende private | 1 |
---|---|
LEO Pharma A/S
![]() LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Patrik Renblad